Collaborative Research and Development AgreementCollaborative Research and Development AgreementCollaborative Research and Development Agreement
Download the document to the computer for easy use
There are more pages to preview,Read on

NEWS
ONCOLYS BIOPHARMA AND SYSMEX CORPORATON SIGN
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR
IN-VITRO CANCER CIRCULATING TUMOR CELL DIAGNOSTIC AGENT

Tokyo, Japan – January 21, 2009 – Oncolys BioPharma Inc. (HQ: Tokyo, Japan;
President & CEO: Yasuo Urata) and Sysmex Corporation (HQ: Kobe, Japan; President:
Hisashi Ietsugu) signed collaborative research and development agreement on GFP gene
containing recombinant adenovirus “TelomeScanTM” (OBP-401). It will be the world’s first
in vitro diagnostic agent for cancers using virus vector to detect circulating living tumor cells
in the blood with high sensitivity.
TelomeScanTM is a telomerase-specific replication-competent adenovirus vector developed
by Oncolys and originally invented by Okayama University, and is containing green fluorescent
protein (GFP) gene, which is the research theme of Dr. Osamu Shimomura, the 2008 Nobel
Prize winner in Chemistry and a senior scientist emeritus and corporation member at the Marine
Biological